NewAmsterdam Pharma Co NV
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
NAMS$19.18+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss)
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
| For the three months ended September 30, | For the nine months ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| (In thousands of USD, except per share amounts) | ||||
| Revenue | 29,111 | 2,941 | 32,791 | 13,287 |
| Operating expenses: | ||||
| Research and development expenses | 35,702 | 43,371 | 116,511 | 118,132 |
| Selling, general and administrative expenses | 18,412 | 9,128 | 49,340 | 27,048 |
| Total operating expenses | 54,114 | 52,499 | 165,851 | 145,180 |
| Operating loss | (25,003) | (49,558) | (133,060) | (131,893) |
| Other income (expense): | ||||
| Interest income | 4,443 | 3,059 | 12,396 | 8,615 |
| Fair value change – earnout and warrants | (770) | 2,521 | (30,028) | (4,004) |
| Foreign exchange gains/(losses) | 4,682 | (3,155) | 1,270 | (160) |
| Loss before tax | (16,648) | (47,133) | (149,422) | (127,442) |
| Income tax expense | (1) | — | (1) | — |
| Loss and comprehensive loss for the period | (16,647) | (47,133) | (149,421) | (127,442) |
| Net loss per ordinary share | ||||
| Basic and diluted | $(0.18) | $(0.57) | $(1.61) | $(1.55) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.